Skip to Content
Biotechnology and health

The health sector is being struck by cyber-espionage

Security researchers say a group of hackers has been targeting firms related to health care in order to steal intellectual property.

The news:  Symantec reports that it’s observed a hacking team, called Orangeworm, compromise the systems of pharmaceutical firms, medical-device manufacturers, health-care providers, and even IT companies working with medical organizations. Victims don’t appear to have been chosen at random but “carefully and deliberately.”

What they’re doing: The point to these hacks doesn’t appear to be theft of patient data like insurance records. Instead, the hackers seem to be looking for intellectual property—such as details of drug manufacturing, or technical details about expensive medical imaging systems.

Who’s doing it? That remains unclear. Symantec says it doesn’t appear to be the work of a nation-state, but rather “an individual or a small group of individuals.” But so far there are no clues within the attacks to reveal who is in the group, or where it’s based.

Why it matters: It’s unusual that a small band of hackers would go after intellectual property in this way, rather than personal details that can be easily sold for cash. That raises questions about who is paying them to gather the information. But the group is clearly doing its job well: it’s attacked over 100 organizations since 2015.

Deep Dive

Biotechnology and health

How scientists traced a mysterious covid case back to six toilets

When wastewater surveillance turns into a hunt for a single infected individual, the ethics get tricky.

An AI-driven “factory of drugs” claims to have hit a big milestone

Insilico is part of a wave of companies betting on AI as the "next amazing revolution" in biology

The quest to legitimize longevity medicine

Longevity clinics offer a mix of services that largely cater to the wealthy. Now there’s a push to establish their work as a credible medical field.

There is a new most expensive drug in the world. Price tag: $4.25 million

But will the latest gene therapy suffer the curse of the costliest drug?

Stay connected

Illustration by Rose Wong

Get the latest updates from
MIT Technology Review

Discover special offers, top stories, upcoming events, and more.

Thank you for submitting your email!

Explore more newsletters

It looks like something went wrong.

We’re having trouble saving your preferences. Try refreshing this page and updating them one more time. If you continue to get this message, reach out to us at customer-service@technologyreview.com with a list of newsletters you’d like to receive.